Final Results of Neuralstem Phase I Stem Cell Trial in ALS Published

The much-anticipated final results from Neuralstem’s Phase I safety trial of intraspinal neural stem cell transplantation for treating ALS were published in the March 7 issue of Annals of Neurology. The report includes data from the six patients who received cervical spinal cord injections in addition to lumbar injections. The final results show that transplantation of these cells at both cervical and lumbar segments can be done safely in human patients. Interestingly, over 50% of the patients participating in the trial demonstrated improvements in functional outcomes measures following treatment. Phase II trials for Neuralstem’s therapy are ongoing (see stories in September 2013 and January 2014).

The much-anticipated final results from Neuralstem’s Phase I safety trial of intraspinal neural stem cell transplantation for treating ALS were published in the March 7 issue of Annals of Neurology. The report includes data from the six patients who received cervical spinal cord injections in addition to lumbar injections. The final results show that transplantation of these cells at both cervical and lumbar segments can be done safely in human patients. Interestingly, over 50% of the patients participating in the trial demonstrated improvements in functional outcomes measures following treatment. Phase II trials for Neuralstem’s therapy are ongoing (see stories in September 2013 and January 2014).

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail